Open AccessFinal results of the prospective multicenter observational program RU-EGD-NI-001 for evaluation of efficacy and tolerability of the 6-month depot Eligard 45 mg in patients with advanced prostate carcinoma in routine clinical practice of uro-oncologists in the Russian Federation
Author(s) -
В. Б. Матвеев,
А. С. Маркова
Publication year - 2017
Publication title -
onkourologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 4
eISSN - 1996-1812
pISSN - 1726-9776
DOI - 10.17650/1726-9776-2017-13-2-79-86
Subject(s) - medicine , tolerability , prostate cancer , leuprorelin , observational study , inclusion and exclusion criteria , clinical trial , population , urology , cancer , surgery , adverse effect , pathology , hormone , gonadotropin releasing hormone , alternative medicine , environmental health , luteinizing hormone